CFTR and cystic fibrosis: Two phase 3 randomized clinical trials (TRAFFIC and TRANSPORT) investigated the comparative safety and efficacy of Orkambi® in patients with CF who were 12 years old and older with mild to moderate lung disease and who were homozygous for the F508del-CFTR mutation [29].